Drugs / ZL-82
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06432738 | Mar → Aug 2024 | — | Chengdu Zenitar Biomedical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06055023 | Apr 2023 → Jan 2024 | inflammatory bowel disease, rheumatoid arthritis | Chengdu Zenitar Biomedical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07193589 | Feb 2026 → Dec 2027 expected | atopic eczema | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-82 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06432738 ↗ |
| Action | Inhibit | “ZL-82 can selectively and irreversibly inhibit JAK3.” NCT06055023 ↗ |
| Modality | Small molecule | “it belongs to Category 1 chemical drugs” NCT06432738 ↗ |
| Route | Oral | “ZL-82 is an oral janus kinase (JAK) inhibitor.” NCT06055023 ↗ |
| Target | JAK3 | “ZL-82 can selectively and irreversibly inhibit JAK3.” NCT06055023 ↗ |